Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/06/01 12:13:49」(JST)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 腎血管筋脂肪腫 renal angiomyolipomas
2. 結節性硬化症の腎症状 renal manifestations of tuberous sclerosis complex
3. 悪性肝腫瘍の病理 pathology of malignant liver tumors
4. 悪性胸膜中皮腫の病理 pathology of malignant pleural mesothelioma
5. 妊娠性絨毛腫瘍：疫学、臨床的特徴、診断、病期分類、およびリスク層別化 gestational trophoblastic neoplasia epidemiology clinical features diagnosis staging and risk stratification

Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype.

Hartmann S, Tousseyn T, Döring C, Flüchter P, Hackstein H, Herreman A, Ponzoni M, de Wolf-Peeters C, Facchetti F, Gascoyne RD, Küppers R, Steidl C, Hansmann ML.SourceSenckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany.
International journal of cancer. Journal international du cancer.Int J Cancer.2013 Dec 1;133(11):2609-18. doi: 10.1002/ijc.28273. Epub 2013 Jun 29.
Abundant macrophage infiltration in tumors often correlates with a poor prognosis. T cell/histiocyte rich large B cell lymphoma (THRLBCL) is a distinct aggressive B cell lymphoma entity showing a high macrophage content. To further elucidate the role of tumor-associated macrophages in THRLBCL, we pe
PMID 23686423

Calretinin is essential for mesothelioma cell growth/survival in vitro: A potential new target for malignant mesothelioma therapy?

Blum W, Schwaller B.SourceAnatomy, Department of Medicine, University of Fribourg, Fribourg, Switzerland.
International journal of cancer. Journal international du cancer.Int J Cancer.2013 Nov;133(9):2077-88. doi: 10.1002/ijc.28218. Epub 2013 Jul 9.
Malignant mesothelioma (MM) are highly aggressive asbestos-related neoplasms, which show strong chemotherapy resistance, and there is no effective cure for MM so far. Calretinin (CR) is widely used as a diagnostic marker for epithelioid and mixed (biphasic) mesothelioma; however, little is known abo
PMID 23595591

CD90 Is a Diagnostic Marker to Differentiate Between Malignant Pleural Mesothelioma and Lung Carcinoma With Immunohistochemistry.

Kawamura K, Hiroshima K, Suzuki T, Chai K, Yamaguchi N, Shingyoji M, Yusa T, Tada Y, Takiguchi Y, Tatsumi K, Shimada H, Tagawa M.SourceDivision of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan; e-mail: mtagawa@chiba-cc.jp.
American journal of clinical pathology.Am J Clin Pathol.2013 Oct;140(4):544-9. doi: 10.1309/AJCPM2Z4NGIIPBGE.
Objectives: To pathologically distinguish mesothelioma from lung carcinoma, particularly adenocarcinoma. Methods: We conducted immunohistochemical analyses on clinical specimens, including 26 cases of mesothelioma, 28 cases of lung adenocarcinoma, and 33 cases of lung squamous cell carcinoma. Result
PMID 24045552